| 2021-STAN-69260 | |
| Researchers at Purdue University have developed new biosensors to detect COVID-19 and other bacterial and viral infections. There are currently two primary diagnostic methods to detect COVID-19, RT-PCR and antigen testing. PCR testing, while accurate, is expensive, time-intensive, and requires careful sample handling. Antigen testing is faster but less accurate. The Purdue researchers' biosensors function by measuring electrical resistance of the applied biological fluid on a 2D layer functionalized with DNA primers. In detecting the SARS-CoV-2 N gene, signal was detected at concentrations as low as 100 copies/microliter. The sensor is highly selective to this gene; the sensor shows nearly no response to SARS-CoV and MERS-CoV N genes. Finally, the sensor maintained sensitivity even using saliva samples, which have a lower burden on patient comfortability than nasopharyngeal swabs. Related Publication: DNA-Functionalized Ti3C2Tx MXenes for Selective and Rapid Detection of SARS-CoV-2 Nucleocapsid Gene. ACS Appl Nano Mater. 2021 Dec 30. DOI: 10.1021/acsanm.1c03520. PMCID: PMC8751632. Technology Validation: The Purdue researchers' method had high selectivity and sensitivity for SARS-CoV-2 N genes in nasopharyngeal and saliva swabs. Advantages - Sensitive - Selective - Can detect pathogens with non-invasive method (saliva sample) - Field-deployable - Point-of-care diagnostic - Fast detection Applications - Biosensor for pathogen detection |
|
|
|
|
Oct 21, 2022
Utility Patent
United States
(None)
(None)
Oct 22, 2021
Provisional-Patent
United States
(None)
(None)
Oct 22, 2021
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
